These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25400013)

  • 41. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
    Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Defining disability: development and validation of a mobility-Disability Severity Index (mDSI) in Charcot-Marie-tooth disease.
    Ramchandren S; Shy M; Feldman E; Carlos R; Siskind C
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):635-9. PubMed ID: 25157034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P₂ phosphatase FIG4.
    Nicholson G; Lenk GM; Reddel SW; Grant AE; Towne CF; Ferguson CJ; Simpson E; Scheuerle A; Yasick M; Hoffman S; Blouin R; Brandt C; Coppola G; Biesecker LG; Batish SD; Meisler MH
    Brain; 2011 Jul; 134(Pt 7):1959-71. PubMed ID: 21705420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetes coexistent with Charcot-Marie-Tooth disease presenting as a recurrent foot ulcer misdiagnosed as diabetic foot: A case report.
    Yan Z; Chen D; Yao L; Wang C; Ran XW
    J Diabetes Investig; 2021 Nov; 12(11):2099-2101. PubMed ID: 33991180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atypical presentation of Charcot-Marie-Tooth disease 1A: A case report.
    Kulkarni SD; Sayed R; Garg M; Patil VA
    Neuromuscul Disord; 2015 Nov; 25(11):916-9. PubMed ID: 26432165
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ataxia and other data reviewed in Charcot-Marie-Tooth and Refsum's disease.
    Salisachs P
    J Neurol Neurosurg Psychiatry; 1982 Dec; 45(12):1085-91. PubMed ID: 6186770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel outcome measures for Charcot-Marie-Tooth disease: validation and reliability of the 6-min walk test and StepWatch(™) Activity Monitor and identification of the walking features related to higher quality of life.
    Padua L; Pazzaglia C; Pareyson D; Schenone A; Aiello A; Fabrizi GM; Cavallaro T; Santoro L; Manganelli F; Gemignani F; Vitetta F; Quattrone A; Mazzeo A; Russo M; Vita G;
    Eur J Neurol; 2016 Aug; 23(8):1343-50. PubMed ID: 27160471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.
    Lewis RA; McDermott MP; Herrmann DN; Hoke A; Clawson LL; Siskind C; Feely SM; Miller LJ; Barohn RJ; Smith P; Luebbe E; Wu X; Shy ME;
    JAMA Neurol; 2013 Aug; 70(8):981-7. PubMed ID: 23797954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The application of scales and characteristics of disability in the common genotypes of Charcot-Marie-Tooth disease].
    Liu X; Zhang RX; Liu L; Xie YZ; Lin ZQ; Zhao Q; Cao WQ; Zhu XY; Li XB
    Zhonghua Yi Xue Za Zhi; 2021 Jan; 101(2):131-136. PubMed ID: 33455129
    [No Abstract]   [Full Text] [Related]  

  • 50. Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A.
    Fledrich R; Mannil M; Leha A; Ehbrecht C; Solari A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Schnizer TJ; Prukop T; Garcia-Angarita N; Czesnik D; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Walter MC; Triaal C; Hogrel JY; Dubourg O; Schenone A; Baets J; De Jonghe P; Shy ME; Horvath R; Pareyson D; Seeman P; Young P; Sereda MW
    J Neurol Neurosurg Psychiatry; 2017 Nov; 88(11):941-952. PubMed ID: 28860329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is Going Beyond Rasch Analysis Necessary to Assess the Construct Validity of a Motor Function Scale?
    Guillot T; Roche S; Rippert P; Hamroun D; Iwaz J; Ecochard R; Vuillerot C;
    Arch Phys Med Rehabil; 2018 Sep; 99(9):1776-1782.e9. PubMed ID: 29625093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of muscle strength, balance and functionality of individuals with type 2 Charcot-Marie-Tooth Disease.
    de França Costa IMP; Nunes PS; de Aquino Neves EL; Lima Santos Barreto LC; Garcez CA; Souza CC; Pereira Oliveira PM; Sales Ferreira LA; Brandão Lima VN; de Souza Araújo AA
    Gait Posture; 2018 May; 62():463-467. PubMed ID: 29674285
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding medication safety and Charcot-Marie-Tooth disease: a patient perspective.
    Socha Hernandez AV; Deeks LS; Shield AJ
    Int J Clin Pharm; 2020 Dec; 42(6):1507-1514. PubMed ID: 32804316
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of gait patterns and functional measures between Charcot-Marie-Tooth disease type I and II in children to young adults.
    Pogemiller K; Garibay E; Pierz K; Acsadi G; Õunpuu S
    Gait Posture; 2020 Mar; 77():236-242. PubMed ID: 32062403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Charcot-Marie-Tooth: From Molecules to Therapy.
    Morena J; Gupta A; Hoyle JC
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study.
    Verhamme C; van Schaik IN; Koelman JH; de Haan RJ; de Visser M
    Brain; 2009 Dec; 132(Pt 12):3252-62. PubMed ID: 19843647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2).
    Engelfried K; Vorgerd M; Hagedorn M; Haas G; Gilles J; Epplen JT; Meins M
    BMC Med Genet; 2006 Jun; 7():53. PubMed ID: 16762064
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of comorbidities on the phenotype of patients affected by Charcot-Marie-Tooth neuropathy type 1A.
    Ursino G; Alberti MA; Grandis M; Reni L; Pareyson D; Bellone E; Gemelli C; Sabatelli M; Pisciotta C; Luigetti M; Santoro L; Massollo L; Schenone A
    Neuromuscul Disord; 2013 Nov; 23(11):902-6. PubMed ID: 23891256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phenotype of Charcot-Marie-Tooth disease Type 2.
    Bienfait HM; Baas F; Koelman JH; de Haan RJ; van Engelen BG; Gabreëls-Festen AA; Ongerboer de Visser BW; Meggouh F; Weterman MA; De Jonghe P; Timmerman V; de Visser M
    Neurology; 2007 May; 68(20):1658-67. PubMed ID: 17502546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Central nervous system signs in X-linked Charcot-Marie-Tooth disease after hyperventilation.
    Srinivasan J; Leventer RJ; Kornberg AJ; Dahl HH; Ryan MM
    Pediatr Neurol; 2008 Apr; 38(4):293-5. PubMed ID: 18358413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.